http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Sang Bong Ahn ),( Dae Won Jun ),( Bo-kyeong Kang ),( Jae Yoon Jeong ),( Joo Hyun Sohn ),( Byoung Kwan Son ) 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: The recently developed MRI-proton density fat fraction (PDFF) is known to be able to measure intrahepatic fat mass relatively accurately. The purpose of this study was to identify the factors affecting the deviation of intrahepatic fat distribution in fatty liver patients using MRI-PDFF, and to suggest an ideal method of measuring intrahepatic fat mass using MRI-PDFF. Methods: We investigated the intrahepatic fat amount using MRI-PDFF and clinical characteristics in 164 patients. Three regions of interest (ROI) were measured for each hepatic lobe using MRI-PDFF to determine the amount of fat in the liver. The total liver fat amount was estimated by multiplying the volume of each lobe by the average fat amount. Results: Segment II had the lowest amount of fat and segment VII had the highest amount of fat. The fat distribution variation was smallest at segment VI and the largest at segment II. When comparing the right lobe with the left lobe, the mean fat mass of the left lobe was low and the standard deviation was severe. The difference in the distribution of intrahepatic fat distribution was higher with young age (r = -0.203, p = 0.009), higher BMI (r = 0.254, p =0.002), high intrahepatic fat amount (r=0.534, p<0.001), high cholesterol (r=0.209, p=0.009) and triglyceride concentration (r = 0.176, p = 0.029). Multivariate analysis showed that intrahepatic fat amount alone was a significant independent risk factor affecting intrahepatic fat distribution heterogeneity. Estimates of total liver fat amount were the most similar to the total fat content in the two lobes at the segment 4 and segment 5. The standard deviation was also significantly lower. Conclusions: The distribution of intrahepatic fat was heterogeneous in patients with fatty liver. It was possible to estimate intrahepatic fat amount ideally for measuring the fat mass in two lobes (segment 4 and 5).
( Bo-kyeong Kang ),( Mimi Kim ),( Dae Won Jun ),( Sang Bong Ahn ),( Eun Jin Kim ),( Jae Yoon Jeong ),( Joo Hyun Sohn ) 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: To reappraise the sensitivity and specificity of ultrasonography in the diagnosis of hepatic steatosis (HS) using MRI proton density fat fraction (PDFF) as a reference standard and to evaluate the diagnostic accuracy of ultrasonography for the grading of HS. Methods: This study includes 184 patients who simultaneously underwent ultrasonography and MRI PDFF between February 2014 and October 2016. Four sonographic parameters were evaluated independently by two radiologists. The hepatic fat fraction is defined as the average of 24 non-overlapping regions of interest (ROIs) obtained by drawing three ROIs within each segment in MRI. The diagnostic performance in assessing the diagnosis and severity of HS was assessed using receiver operating characteristic (ROC) analyses. Results: Abnormal hepatorenal echoes and loss of echogenicity of the portal vein were good surrogate markers for the diagnosis of HS. There was a strongly positive correlation between the sonographic findings and hepatic fat fraction (r=0.754, P<0.001). A sensitivity of 96.6% and a specificity of 74.8% were achieved by using abnormal hepatorenal echoes to diagnose mild fatty liver, with a value of area under the ROC curve (AUROC) of 0.875. Loss of echogenicity of the portal vein with abnormal hepatorenal echoes had a sensitivity of 100%, a specificity of 85.9%, and an AUROC of 0.930 in detecting moderate fatty liver. Conclusions: The sensitivity and specificity for the detection of mild fatty liver with ultrasonography were excellent. Abnormal hepatorenal echoes and/or loss of echogenicity of the portal vein were relevant surrogate markers to diagnose fatty liver.
( Sang-bo Kim ),( Na Young Yoon ),( Kil-bo Shim ),( Chi-won Lim ) 한국수산과학회(구 한국수산학회) 2016 Fisheries and Aquatic Sciences Vol.19 No.3
In the present study, we investigated to the antioxidant and angiotensin I-converting enzyme (ACE) inhibitory activities of the northern shrimp (Pandalus borealis) by-products (PBB) hydrolysates prepared by enzymatic hydrolysis. The antioxidant and ACE inhibitory activities of five enzymatic hydrolysates (alcalase, protamex, flavourzyme, papain, and trypsin) of PBB were evaluated by the 2, 2′-azino-bis [3-ethylbenzothiazoline-6-sulfonic acid] (ABTS+) radical scavenging and superoxide dismutase (SOD)-like activities, reducing power and Li’s method for ACE inhibitory activity. Of these PBB hydrolysates, the protamex hydrolysate exhibited the most potent ACE inhibitory activity with IC50 value of 0.08 ± 0.00 mg/mL. The PBB protamex hydrolysate was fractionated by two ultrafiltration membranes with 3 and 10 kDa (below 3 kDa, between 3 and 10 kDa, and above 10 kDa). These three fractions were evaluated for the total amino acids composition, antioxidant, and ACE inhibitory activities. Among these fractions, the < 3 kDa and 3.10 kDa fractions showed more potent ABTS+ radical scavenging activity than that of > 10 kDa fraction, while the > 10 kDa fraction exhibited the significant reducing power than others. In addition, 3.10 kDa and > 10 kDa fractions showed the significant ACE inhibitory activity. These results suggested that the high molecular weight enzymatic hydrolysate derived from PBB could be used for control oxidative stress and prevent hypertension.
( Bo Ram Lee ),( Yu Il Kim ),( Chul Min Ahn ),( Ji Ye Jung ),( Ju Ock Kim ),( Jin Young An ),( Hyoung Kyu Yoon ),( Sang Haak Lee ),( Yeong Hun Choe ),( Chang Hoon Han ),( Joo Hun Park ),( Jae Yeol Kim 대한결핵 및 호흡기학회 2014 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.118 No.-
Background: A simple chest x-ray (CXR) is commonly used to examine the chest and lung disease. There are few reports on the prevalence of CXR abnormalities in the general population. We aimed to investigate the prevalence of abnormalities seen on CXR in the general population and risk factors including smoking associated with these abnormalities. Methods: We analyzed the data of the 4th and 5th Korea National Health and Nutrition Examination Survey; a cross-sectional survey in the general population of Korea. A total of 27,936 subjects aged 19 years or more were enrolled in this study. CXR findings were categorized into 5 groups; normal, tuberculosis (active or inactive), lung nodule or cancer or mediastinal disease, active other lung diseases, inactive other lung diseases. The amount of smoking was classified as never, =15 pack-years, and >15 pack-years. Results: The prevalence of CXR abnormalities was 12.8 % (n=3180); 9.5% in never-smokers, 9.9% in smokers who had smoked =15 pack-years, 19.1% in smokers who had smoked >15 pack-years. The most common abnormal finding was pulmonary tuberculosis. Significant independent risk factors for CXR abnormalities by multivariate analysis were age (40-59 years: odds ratio [OR], 3.40; 95% confidence interval [CI], 2.93 - 3.93; = 60 years: OR, 9.81; 95% CI, 8.52 - 11.29), sex (male) (OR, 1.68; 95% CI, 1.50 - 1.88) and smoking amount (>15 pack-years) (OR, 1.19; 95% CI, 1.05 - 1.35). Conclusions: Abnormalities on CXR were more prevalent in moderate to heavy smokers, older subjects and men in the general population. The prevalence increased with increased amount of smoking. Since cigarette smoking is a preventable risk factor for lung disease, efforts are needed for smoking cessation in the community.
S-297 Prognostic Value of CA125 with NT-proBNP in Patients with Acute Heart Failure
( Bo Eun Park ),( Yoon Jung Park ),( Jong Sung Park ),( Se Yong Jang ),( Myung Hwan Bae ),( Jang Hoon Lee ),( Dong Heon Yang ),( Hun Sik Park ),( Yongkeun Cho ),( Shung Chull Chae ) 대한내과학회 2016 대한내과학회 추계학술대회 Vol.2016 No.1
Background: Carbohydrate antigen-125 (CA-125) is an emerging prognostic biomarker in heart failure. We aimed to test the long term prognostic value of CA-125 in combination with N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with acute decompensated heart failure. Methods: A total of 419 patients (64.1±15.6 years-old, 214 men) suffered acute decompensated heart failure between 2005. Jan and 2013. July were retrospectively enrolled. All-cause mortality during 2 years follow-up was investigated for the prognosis of the patients Results: During follow-up, 109 (26.0%) deaths were recorded. In multivariable analysis model, CA-125 was an independent prognostic marker (log CA-125 hazard ratio 1.23 [1.02-1.48], p=0.030) together with age, sex, NYHA class, β-blocker use, inotropics use and NT-proBNP level. We divided the study cohort into 4 groups according to the levels of NT-proBNP (cufoff value 5269 pg/ml for 2-year survival) and CA-125 (cutoff value 54.5 U/ml for 2-year survival). Kaplan-Meier survival analysis demonstrated that the group with both low marker levels showed best 2-year survival (87.9%) followed by the group with low NT-proBNP and high CA-125 level (76.1%), high NT-proBNP and low CA-125 (64.7%) and high NT-proBNP and high CA-125 (54.3%) (p<0.001). Likelihood ratio test showed that addition of NT-proBNP level to established risk factors increase the predictive power for mortality (global chi-square from 130.6 to 138.3, p=0.005. Addition of CA-125 on the top of the combination of NT-proBNP and established risk factors still more increased the predictive power for mortality (global chi-square from 138.2 to 143.3, p=0.026) in patients with acute decompensated heart failure. Conclusions: CA-125 was an independent prognostic marker in patients with acute decompensated heart failure. Combined use of CA-125 and NT-proBNP provided a significant improvement in prediction of mortality in patients with acute decompensated heart failure.